Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) to Present at Second Annual Advances in Immuno-Oncology USA Congress and World Immunotherapy Congress

INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that its Co-Founder and CEO RJ Tesi, M.D., will present at the 2nd Annual Advances in Immuno-Oncology USA Congress taking place on October 8-9 in San Diego. In addition, Dr. Tesi and Director of Neuroscience CJ Barnum, Ph.D., will present at the World Immunotherapy Congress taking place from October 15-17 in Basel, Switzerland. “The immuno-oncology field is rapidly growing, and emerging new therapies are at the center of attention,” Dr. Tesi said in the news release. “With 30% of breast cancer patients being HER2+, trastuzumab has made significant strides in the treatment of breast cancer. Yet, many HER2+ breast cancer patients have shown resistance to the drug. In my presentation during the Advances in Immuno-Oncology USA Congress, I will address one of the reasons for the resistance – specifically the presence of the MUC4 biomarker – and how we may be able to use a soluble TNF inhibitor, such as our drug candidate INB03, to increase the efficacy of trastuzumab in those women who have shown resistance.”

To view the full press release, visit

About INmune Bio, Inc.

INmune Bio, Inc. is a publicly traded, clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (“NK”) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid-derived suppressor cells (“MDSC”), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published:

This entry was posted in INmune Bio Inc. INMB, MissionIRNewsBreaks. Bookmark the permalink.

Comments are closed.